Diagnosis & Treatment Blogs

Updated: June 10, 2025 Editor's Note: This important research project is already yielding many tangible results, including being published in the Annals of the American Thoracic

Read time: 2 minutes. Brain metastases (also called brain mets) develop when cancer from somewhere else in the body spreads to the brain. Over time, tumors can become metastatic

Read time: 4 minutes. Editor's Note: This article has been updated for 2025 as LUNGevity and ALCSI continue their partnership for Lung Cancer Awareness Month. Anyone with lungs can

Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug

On August 15, 2024, the US Food and Drug Administration (FDA) approved a new treatment regimen for people newly diagnosed with early-stage, resectable (able to be removed by

On August 19, 2024, the US Food and Drug Administration (FDA) approved a new treatment option for people newly diagnosed with locally advanced or metastatic non-small cell lung

Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming

Read time: 2 minutes. Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell

Read time: 3 minutes. Editors Note: If you missed the 2024 International Lung Cancer Survivorship Conference (ILCSC), make sure to join our email list and be the first to know when

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with

Read time: 1 minute On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK